Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Felcisetrag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 20/20 | 0.98 |
| ▸ | HTR3A | P46098 | 16/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Felcisetrag SCHEMBL390795 | 0.99 | HTR4 (1.00) | HTR4HTR3A | |
| SCHEMBL827475 | 0.92 | HTR4 (0.86) | HTR4HTR3A | |
| SCHEMBL828330 | 0.91 | HTR4 (0.85) | HTR4HTR3A | |
| SCHEMBL1724211 | 0.91 | HTR4 (0.87) | HTR4HTR3A | |
| SCHEMBL828734 | 0.90 | HTR4 (0.84) | HTR4HTR3A | |
| SCHEMBL1726589 | 0.88 | HTR4 (0.80) | HTR4HTR3A | |
| SCHEMBL828983 | 0.88 | HTR4 (0.82) | HTR4HTR3A | |
| SCHEMBL27850731 | 0.88 | HTR4 (0.82) | HTR4HTR3A | |
| SCHEMBL29397319 | 0.88 | HTR4 (0.82) | HTR4HTR3A | |
| SCHEMBL28074651 | 0.87 | HTR4 (0.80) | HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622587-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | claimed |
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.